-

Agathos Biologics Launches Analytical Services

Initial offerings focus on high-content imaging and digital PCR

FARGO, N.D.--(BUSINESS WIRE)--Agathos Biologics, a leading biotechnology company, is proud to offer advanced analytical testing services for life science researchers. With a focus on high-content imaging and digital PCR, our team of experienced scientists use state-of-the-art technology to deliver unparalleled accuracy and reliability in nucleic acid quantification and cell analysis.

The first of its kind within the region, Agathos’ high-content imaging services allow the capture and analysis of multiple parameters within a cell, providing a more comprehensive understanding of biology than ever before. With various imaging applications, including immunohistochemistry, immunofluorescence, and signaling pathways, our experienced scientists can now offer the best imaging experiments available.

Agathos Biologics uses the latest digital PCR (dPCR) technology, delivering unparalleled sensitivity and precision in nucleic acid quantification. dPCR methods can detect and quantitate low concentrations of target nucleic acid sequences with high accuracy, making it a powerful tool for mutation analysis, viral vector titer determination, and pathogen detection. Agathos exclusively uses QIAcuity instrumentation and assays from QIAGEN and has collaborated with QIAGEN in mycoplasma and recombinant adeno-associated viral vector (rAAV) assay testing and validation.

“Our goal is to advance biotechnology and genetic medicine with products and services through ethical innovation,” said James Brown, CEO and co-founder of Agathos. “As we develop capabilities for our internal research and development, we have the opportunity to make these high-content imaging and digital PCR services available to clients in our region and beyond. These services represent the first step in our strategy to create breakthrough products and services within a strong ethical and moral framework that benefit everyone.” For more information on high-content imaging and dPCR, visit Agathos Services on our web site.

About Agathos

Agathos Biologics is a biotechnology company pursuing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy. Discoveries in bioprocessing and genetic characterization and control have created an abundance of scientific possibilities that can help us all lead better lives. Our mission as The Good Science Company is to create breakthrough products and services within a strong ethical and moral framework that benefit everyone. We believe in science that serves and have a relentless focus on serving our clients, employees, and society. For more information, please visit www.agathos.bio.

Contacts

James Brown, Ph.D.
CEO
james.brown@agathos.bio
+1-701-415-3395

Agathos Biologics


Release Summary
Agathos Biologics launches analytical services with a focus on high-content imaging and digital PCR.
Release Versions

Contacts

James Brown, Ph.D.
CEO
james.brown@agathos.bio
+1-701-415-3395

More News From Agathos Biologics

Agathos Biologics Launches Recombinant Adeno-Associated Virus Production Service Using Novel AE1-BHK Cell Line

FARGO, N.D.--(BUSINESS WIRE)--Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK. The company recorded its first sale of rAAV to Genovac, a contract research and manufacturing organization (CRO/CMO) that discovers, develops, and manufactures antibodies for therapeutic, diagnostic, and research market segments. Agathos produc...

Agathos Biologics to present data on cell lines for viral vector production

FARGO, N.D.--(BUSINESS WIRE)--Agathos Biologics, a leading biotechnology company in genetic medicine, will present data at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) from research to develop methods for production of rAAV. The company has developed a cell line based on BHK-21 that it transformed with a plasmid containing the E1 gene of adenovirus. The data show rAAV production with this cell line, Agathos BHK-[wt E1], using a standard triple transfection me...

Agathos Expands Laboratory Space to Support Genetic Medicine and Biomanufacturing Development

FARGO, N.D.--(BUSINESS WIRE)--Agathos Biologics announced today that it has signed a lease with Comstock Companies to acquire additional laboratory and office space, bringing its total to 10,000 square feet of usable space. “We are excited to expand our footprint in Fargo, North Dakota, which continues to see growth in its biotechnology industry,” said James Brown, CEO of Agathos. “The space is purpose-built for laboratory research, which will allow us to immediately increase our capacity to su...
Back to Newsroom